|
| Press Releases |
|
 |
|
| Tuesday, September 14, 2021 |
|
|
Eisai to Join The Global Environmental Initiative "RE100" |
| Eisai Co., Ltd. announced today that it has joined "RE100", the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity. more info >> |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021 |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its oncology products and pipeline will be given at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, from September 16 to 21, 2021, including its in-house discovered lenvatinib mesylate and eribulin mesylate. more info >> |
|
| Monday, September 13, 2021 |
|
|
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients" |
| AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched "Humira Support Tool Ordering Service for Patients" an initiative intended to improve patients' adherence to Humira therapy. more info >> |
|
| Tuesday, August 31, 2021 |
|
|
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries |
| Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand. more info >> |
|
| Monday, August 16, 2021 |
|
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide), in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
| Thursday, August 12, 2021 |
|
|
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC) |
| Eisai and Merck & Co., Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
| Thursday, August 5, 2021 |
|
|
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards |
| Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo). more info >> |
|
| Monday, August 2, 2021 |
|
|
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures |
| Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older" in China from the National Medical Products Administration. more info >> |
|
| Friday, July 30, 2021 |
|
|
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401) |
| Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) -- granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021. more info >> |
|
|
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021 |
| Biogen and Eisai Co., Ltd. today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer's disease called ICARE AD-US, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
FULONGMA heralds Thailand's EV sanitation equipment breakthrough 
Sept 17, 2021 11:34 HKT/SGT
|
|
|
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
Sept 17, 2021 08:40 HKT/SGT
|
|
|
UREEQA Announces New Qards Campaign, Staking Pools and Tier Structure
Sept 16, 2021 21:00 HKT/SGT
|
|
|
Honda Exhibits the World Premiere of All-new BF150, BF135 and BF115 Large-size Marine Outboard Engines at the Genoa International Boat Show 2021
Sept 16, 2021 18:08 HKT/SGT
|
|
|
Huisen and Xiaomi Formed A Strategic Cooperation to Develop Smart Home Business
Sept 16, 2021 15:16 HKT/SGT
|
|
|
Applus+ IDIADA and MHI Group to Develop Testing and Verification System for Highly Automated Vehicles
Sept 16, 2021 13:52 HKT/SGT
|
|
|
Hatten Land Enters into MOU with Singapore Myanmar Investco to Undertake 'Green' Crypto Mining Activities in Melaka
Sept 16, 2021 08:45 HKT/SGT
|
|
|
AppSealing Introduces Data Encryption Solution for Android Apps
Sept 16, 2021 08:00 HKT/SGT
|
|
|
AppSealing Introduces Data Encryption Solution for Android Apps
Sept 16, 2021 08:00 HKT/SGT
|
|
|
Copying the small structures of Salvinia leaves
Sept 16, 2021 06:00 HKT/SGT
|
|
|
ICCPP Holds GENE TREE Online Roundtable
Sept 16, 2021 03:00 HKT/SGT
|
|
|
RCEP Qingdao Design Festival opens September 17
Sept 16, 2021 02:00 HKT/SGT
|
|
|
CakePunks, the NFT Project Disrupting the Decentralised Collectible Space
Sept 15, 2021 22:00 HKT/SGT
|
|
|
CRAFTLAND Announces the Launch of Its Platform, Recycling Altcoins to Help Investors
Sept 15, 2021 22:00 HKT/SGT
|
|
|
Honda: Takahisa Fujinami to End 26-Year Trial World Championship Career
Sept 15, 2021 18:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
